期刊
JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
卷 11, 期 8, 页码 2304-2313出版社
WILEY
DOI: 10.1002/term.2129
关键词
cardiac regeneration; cell therapy; fibrin; myocardial infarction; patch; scaffold; tissue engineering
类别
资金
- Ministerio de Educacion y Ciencia [SAF2011-30067-C02-01, SAF2014-59892-R]
- Fundacio La MARATO de TV3 [122232, 201502, 201516]
- Red de Terapia Celular - TerCel [RD12/0019/0029]
- Red de Investigacion Cardiovascular - RIC [RD12/0042/0047]
- Sociedad Espanola de Cardiologia
- Societat Catalana de Cardiologia
- Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III as part of the Plan Nacional de I+D+I [FIS PI14/01682]
Fibrin is a topical haemostat, sealant and tissue glue, which consists of concentrated fibrinogen and thrombin. It has broad medical and research uses. Recently, several studies have shown that engineered patches comprising mixtures of biological or synthetic materials and progenitor cells showed therapeutic promise for regenerating damaged tissues. In that context, fibrin maintains cell adherence at the site of injury, where cells are required for tissue repair, and offers a nurturing environment that protects implanted cells without interfering with their expected benefit. Here we review the past, present and future uses of fibrin, with a focus on its use as a scaffold material for cardiac repair. Fibrin patches filled with regenerative cells can be placed over the scarring myocardium; this methodology avoids many of the drawbacks of conventional cell-infusion systems. Advantages of using fibrin also include extraction from the patient's blood, an easy readjustment and implantation procedure, increase in viability and early proliferation of delivered cells, and benefits even with the patch alone. In line with this, we discuss the numerous preclinical studies that have used fibrin-cell patches, the practical issues inherent in their generation, and the necessary process of scaling-up from animal models to patients. In the light of the data presented, fibrin stands out as a valuable biomaterial for delivering cells to damaged tissue and for promoting beneficial effects. However, before the fibrin scaffold can be translated from bench to bedside, many issues must be explored further, including suboptimal survival and limited migration of the implanted cells to underlying ischaemic myocardium. Copyright (c) 2016 John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据